FDA approves AstraZeneca's Imfinzi-chemo combo for advanced endometrial cancer in US

Published: 17-Jun-2024
Regulatory

Imfinzi reduced the risk of disease progression and death compared to chemotherapy alone by 58% in the recent Phase III DUO-E trial

AstraZeneca, a global pharmaceutical company, has received US FDA approval for the use of Imfinzi (durvalumab) in combination with carboplatin and paclitaxel to treat adults with primary advanced or recurrent endometrial cancer.

The combination therapy is designed to treat patients who are mismatch repair deficient (dMMR), and its approval has come off the back of the DUO-E Phase III trial — which was published in the Journal of Clinical Oncology.1


The results

In the trial, Imfinzi plus carboplatin and paclitaxel followed by Imfinzi monotherapy (Imfinzi arm) reduced the risk of disease progression or death by 58% in patients with dMMR endometrial cancer versus chemotherapy alone.2

Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and principal investigator of the trial, Shannon N. Westin, said: “With the prevalence of endometrial cancer expected to increase, it’s more important than ever that we bring new treatment options to patients at the earliest possible moment in their care. This approval underlines clear evidence that durvalumab plus chemotherapy followed by durvalumab monotherapy delivers important clinical benefits for patients with mismatch repair deficient endometrial cancer.”

 

Safety and tolerability profile

The safety profile of the Imfinzi-chemotherapy combination was generally manageable and tolerated in the patient population; with the results aligning with prior clinical trials.1,2

The Lynparza (olaparib) and Imfinzi arm, which investigated Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza as maintenance therapy, also met the primary endpoint of progression-free survival (PFS). 

The trial continues to assess OS as a key secondary endpoint for both arms. 

Regulatory applications for both Imfinzi as well as Imfinzi and Lynparza regimens are currently under review in the EU, Japan and several other countries based on the DUO-E results.

 
 

References

1  Imfinzi (durvalumab) US prescribing information; Jun 2024.

2  Shannon N. Westin et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. JCO 42, 283-299(2024).

  • Companies:
  • AstraZeneca
See more

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

Read more
The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

AstraZeneca's Imfinzi gains FDA approval for limited-stage small cell lung cancer

The immunotherapy has been approved based on the results of the Phase III ADRIATIC clinical trial, which evaluated the benefits of durvalumab in patients with limited-stage SCLC
Regulatory

AstraZeneca's Wainzua recommended for EU approval to treat amyloidosis

The neuropathy drug was developed in tandem with Ionis, and has been shown to reduce neuropathy and increase quality of life in the Phase III NEURO-TTransform trial
Regulatory

AstraZeneca's Tagrisso obtains FDA approval for use in stage III NSCLC

Tagrisso reduced the risk of disease progression or death by 84% compared to placebo in the Phase III LAURA trial
Regulatory

AstraZeneca's Fasenra for severe eosinophilic asthma approved in China

The NMPA approval stems from the results of the MIRACLE Phase III trial, which found a 74% reduction in the annualised asthma exacerbation rate
Regulatory

AstraZeneca's Imfinzi granted priority review and BTD by the US FDA for SCLC

The therapeutic significantly improved PFS and OS in patients with limited-stage small cell lung cancer in the Phase III ADRIATIC trial
Regulatory

AstraZeneca & Daiichi Sankyo's Enhertu bags another approval for gastric cancer applications

The HER2-targeting ADC has received conditional approval owing to the results of the DESTINY-Gastric06 Phase II trial
Regulatory

Tagrisso plus chemo for advanced lung cancer approved in the EU

Tagrisso and chemotherapy improved progression-free survival by 38% when compared with monotherapy alone
Subscribe now